|
|
|
|
|
Conference coverage
that stands out
Conference 360® is a comprehensive conference media coverage platform that offers your brand share-of-voice around a conference of your choosing. Coverage includes videos with key opinion leaders, daily updates to the HCPLive® network of clinicians, and key takeaways on conference presentations, adjunct symposia, and poster sessions.
Your opportunity includes:
|
100% SOV advertising
|
|
|
4 eNewsletter deployments to key HCP targets with 100% SOV
|
|
|
Premium advertising around KOL commentary of late breakers, data releases and key takeaways from
the meeting
|
|
|
Conference landing pages promoted through search, social media channels, email and additional
digital marketing tactics
|
|
|
|
At HCPLive®, we cover more
than 50 congresses including:
American Academy of Allergy,
Asthma & Immunology (AAAAI)
American Academy of Dermatology
Alzheimer's Association International
Congress (AAIC)
American College of Allergy, Asthma,
and Immunology (ACAAI)
American College of Cardiology
Scientific Session and Expo
American College of Chest Physicians (CHEST)
American College of Gastroenterology (ACG)
American College of Rheumatology (ACR)
American Diabetes Association (ADA)
American Heart Association (AHA)
American Psychiatric Association Meeting
American Society of Hematology (ASH)
American Thoracic Society (ATS)
Digestive Disease Week (DDW)
European Congress of Rheumatology (EULAR)
Contact us today to discuss how we can provide the contextual alignment your brand deserves.
CONTACT US
|
|
|
|
Featured Specialists
Karl Csaky, MD, PhD
Nancy L. Holekamp, MD
Jennifer I. Lim, MD
Carl Regillo, MD, FACS
Lloyd Clark, MD
|
|
|
|
|
Advances in the Management of Age-Related Macular Degeneration
|
|
|
|
EP 2: |
Age-Related Macular
Degeneration Diagnosis
Duration 5:55
|
|
|
EP 3: |
Specialist Referrals and Therapy Goals for Patients With AMD
Duration 6:08
|
|
EP 4: |
Anti-VEGF Agent Therapy Considerations for
Patients With AMD
Duration 5:55
|
|
|
EP 5: |
Anti-VEGF
Agent Safety
Duration 7:48
|
|
EP 6: |
Additional Diagnostic Tools for Anti-VEGF Agents and Using Brolucizumab
Duration 6:56
|
|
|
EP 7: |
Faricimab and TENAYA
and LUCERNE Trials
Duration 9:38
|
|
EP 8: |
YOSEMITE and RHINE Trials for Patients With Diabetes and AMD
Duration 4:17
|
|
|
EP 9: |
VEGF Inhibitors With Potential to Treat AMD: Port Delivery System
Duration 1:07
|
|
EP 10: |
VEGF Inhibitors With Potential to Treat AMD: KSI-301
Duration 4:04
|
|
|
EP 11: |
Unmet Needs for
Patients With AMD
Duration 9:13
|
|
|
|
|
HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.
|
|
|
|